Good morning :)
$
₹
Opko Health Inc

Opko Health Inc

OPK

NASDAQ
Asset Logo

Opko Health Inc

OPK

NASDAQ
$1.773.19% (+0.05)
$
₹
$1.773.19% (+0.05)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Diagnostics & Research

Small Cap

With a market cap of $1.3B the stock is ranked 2551

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.04
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.09
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

93.64
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-12.4%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 6 analysts reports

Buy
5 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+141.28%

Earnings Growth

-16.67%

Rev. Growth

-6.1%

See Detailed Forecast

Company Profile

Company Profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
36.27%
36.27%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
58.2%
58.2%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
37.21%
37.21%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
24.59%
24.59%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
51.74%
51.74%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 141.28% growth, versus a trailing 3-year CAGR of 8.41%.

2026
Current$1.72Baseline
Analyst Target - 1 year
Target$4.15+141.28%

All values in $

202220232024202520262027$1.99$2.85$3.71Target+141.28%
2026
Current$1.72Baseline
Analyst Target - 1 year
Target$4.15+141.28%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -6.10% growth, versus a trailing 3-year CAGR of -15.45%.

2025
Current$0.60Baseline
Forecast for Dec 2026
High$0.57-5.62%
Average$0.56-6.1%
Low$0.56-6.67%

All values in $ Billion

2021202220232024202520261.771.000.860.710.60Low-6.67%Average-6.1%High-5.62%
2025
Current$0.60Baseline
Forecast for Dec 2026
High$0.57-5.62%
Average$0.56-6.1%
Low$0.56-6.67%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.18Baseline
Forecast for Dec 2026
High$-0.2-11.11%
Average$-0.21-16.67%
Low$-0.22-22.22%

All values in $

202120222023202420252026-0.05-0.44-0.25-0.09-0.18Low-22.22%Average-16.67%High-11.11%
2025
Current$-0.18Baseline
Forecast for Dec 2026
High$-0.2-11.11%
Average$-0.21-16.67%
Low$-0.22-22.22%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

151.6
21.6
148.4
-31.2
124.1
-54.8
163.5
-8.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue173.68182.18173.63183.63149.95156.80151.66148.45124.19163.58
Net Income-81.83-10.3024.8914.02-67.61-148.4421.63-31.25-54.84-8.41
Net Profit Margin-47.11%-5.65%14.33%7.63%-45.08%-94.66%14.26%-21.05%-44.16%-5.14%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Opko Health Inc -1.0493.64
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare OPK with any stock or ETF
Compare OPK with any stock or ETF
Comparing from
OPK
ABBV
AMGN
Loading...

Frequently asked questions

  1. Opko Health Inc (OPK) share price today is $1.77 as of November 5, 2026 at 12:25 AM IST. The stock touched a day high of $1.79 and a day low of $1.75.

  2. Opko Health Inc stock trades on NASDAQ under the ticker symbol OPK.

  3. Opko Health Inc's market capitalization is $1.28B as of November 5, 2026 at 12:25 AM IST.

  4. Opko Health Inc's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Opko Health Inc's price-to-book (P/B) ratio is 1.04 as of November 4, 2026.

  6. Yes, You can buy Opko Health Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Opko Health Inc shares in three steps: 1. Search Opko Health Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Opko Health Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Opko Health Inc (OPK) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 5.6338 shares at the current price of $1.77.

Loading...